Index

Note: page numbers in *italics* refer to figures and tables

abruptio placenta 7
access to treatment 200–201
adenosine triphosphate (ATP)
  local regulation 40–41
  mitochondria in developmental competence 37–38
  mitochondrial polarity in generation 40–41
  oocyte content 38–40
  production in cleavage 98
  requirement at blastulation 98–99
  spatial differences in generation 40
age factors 153
  elective SET 274
  female 174
  implantation rate 96
American Society for Reproductive Medicine (ASRM) 256–257
amniodrainage, serial aggressive 10–11
aneuploidy 18
  blastomere asymmetry 274
  multinucleation 274
  pronuclei score correlation 112
  rate in women of advanced reproductive age 62
  screening 62, 103, 104, 105
  *see also* preimplantation genetic aneuploidy screening
Angelman syndrome 217
angiogenesis stimulation, follicle oxygen perfusion 31
anti-Müllerian hormone (AMH) 30, 42
  perifollicular flow rate 31
anxiety 152, 161–163
  dropout rate 166
  pregnancy rate 163
Apgar score, low in neonatal morbidity 9
assisted reproductive technology (ART)  283
advances  283
interested parties  262
multiple birth incidence  4
outcome  283–284
expression  284
redefinition  160
registration of practice  284
regulation  249
twins  12–13
autonomy, patient  154, 199–200
rationality  201–205
respect for  206–207
risk acceptance decisions  201
US  276

Beckwith–Wiedemann syndrome  217
behavioral medicine program  164
Belgian model  56, 75, 284–285
cost-effectiveness  228
exceptions  61
funding  58, 58–59, 285
insurance coverage  251
legally enforced SET  57–61
number of embryos transferred  58–61
twin pregnancy reduction  285

beneficence principle  200
bioenergetic capacity, oocytes  38–39
bioenergetic thresholds  37–38
birth rate
Dutch experience with SET  192
Swedish experience  186
see also live birth
birth weight
comparison between SET and DET  78–79
intrapair discordance  8–9
multiple pregnancies  8–9
singleton  234
from single gestation/loss of one gestational sac  87

blastocyst(s)  105–106
anaerobic metabolism  98–99
assisted hatching of frozen-thawed  130
biopsy  100
aneuploidy screening  103, 104
timing  101–103
chromosomal complement  99
cryopreservation  128, 132
day 5 and day 6  130–131
implantation rate  130–131
live birth rate  131
optimization  130–131
optimized program  131
outcomes  132
culture
contribution to eSET  98–100
embryo selection  29

development
potential  26–28
prolongation  26–29
spERM quality  244–245
evaluation  132
formation and sperm origin  242–243
frozen-thawed  131, 132
implantation
probability  99
rate  131
inner cell mass  127
post-thaw survival  130
mitotic nondisjunction  106
morphology  115–116
oocyte recipients  136
outcome of single transfer  99
quality  116
scoring systems  116, 285–286
vitrification  131

blastocyst transfer  61
compared with embryo cleavage stage transfer  71
embryo day 3 transfer comparison  214–215
embryo donation impact  140
implantation rate  214
monzygotic twinning  215–216
outcomes  130, 132, 214, 285–286
regulation/self-regulation  252
of two  128, 128–129
US experience  127–128
viability loss  213
see also elective single blastocyst transfer (eSBT); single
blastocyst transfer (SBT)

blastomeres
asymmetry in aneuploidy  274
biopsy  148, 149, 286
disproportionate size  23
embryo fragmentation during cleavage  25–26
four-cell embryos  113
mitochondrial maldistribution  39
nucleation  114, 114, 285–286
number  285–286
Index

size 113, 113, 115
trisomic 148
blastulation
ATP requirement 98–99
embryo biopsy after 101–103
burden minimization 199–200
Canada, legislation 260
causal contribution 206
Cdx2 transcription factor, distribution 22–23
causal contribution 206
Cesarean section
monoamniotic twins 11
multiple births 6
children
health 284
welfare regulation/self-regulation 252
see also infant mortality; neonatal entries
chorionicity 4–5, 8
chromatin, NPB co-localization 24
chromosomal abnormalities 18
preimplantation genetic screening 147, 148
vanishing twin syndrome 86
clinical guidelines
eSET 176
United States 256–257
conception
early 83–89
mind–body interventions 164
conceptus status 253–254
conditional treatment 206
congenital malformations
IVF singletons 89
multiple pregnancies 9–10, 270
coping strategies
infertility 165
in vitro fertilization 162
cortisol:cortisone follicular ratio 30
cost(s)
direct 224
hospital newborn 225
incremental cost-effectiveness ratio 224–225
incremental for SET and DET 227
indirect 224
maternal 225
multiple births 225
multiple pregnancies 200, 225
per patient for SET and DET 227
twin pregnancies 225
for society 75
cost descriptions 223–224
cost-effectiveness 200, 223–229
health-economic analysis 223–225
cost-effectiveness analysis 224
Belgian model 228
decision-making 227–228
Dutch experience with SET 192, 192, 194, 196–197
perspective 224
published trials 227
randomized controlled trials 225–226
United States 228
cost-minimization studies 224
cost–outcome descriptions 223–224
counseling 151–157
communication 154–155
cryopreservation information 156
decision-making
approaches 155–157
impact 203
over multiple pregnancies 153–155
Dutch experience with SET 194–195
effectiveness 165
extent 154
medical SET 57
message delivery 155
multiple pregnancies 10, 153–155
oocyte donation 136
Index

292

Counseling (cont.)
outcomes 164
patient autonomy 154
psychological context of eSET 151–152
psychological outcomes 164
psychosocial risk 156
risk
multiple gestation/birth 156
psychosocial 156
statistics 155–156
selective fetal reduction 156
skills of IVF professionals 174
criterion, primary 237
cryo-augmentation
after SET 121–125, 127–132
pregnancy rate per cycle 75
single blastocyst transfer impact 131–132
cryopreservation xiv, 121–125, 287
American experience 127–132
blastocysts 132
day 5 and day 6 130–131
optimization 130–131
transfer 128
counseling 156
Dutch experience with SET 196
embryos available 186
eSET programs 122–123
European countries 121
good results 178
health-economics 124
implantation rate 124
lack of sufficient program 173
non-optimal patients 123
optimal ovarian stimulation 124
outcome 123–124
pregnancy rate 122
programs 121–122
regulation/self-regulation 251–252
studies in 1990s 121–122
success rate 276
techniques 123–124
culture medium 217
embryo metabolism 286
cumulative singleton delivery rate (CUSIDERA) 235
cumulative twin delivery rate (CUTWIDERA) 235
cumulus cells
follicle-specific differences in bioactivity 35–36
gap junction-bearing cytoplasmic processes 98
gene expression association with competence 36
phenotypes 35, 43
cyclo oxygenase 2 (COX-2) gene 34
cyclophosphamide 241
cytokinesis, abnormal 113
cytoplasmic dysmorphisms 18
cytoplasmic flare 23
cytoplasmic halo 23
scoring for sequential embryo selection 111–112
decision-making
clinical practice context 227–228
cost-effectiveness analysis 227–228
counseling
approaches 155–157
impact 203
for multiple pregnancies 153–155
couple involvement 176–177
eSET 172
health economics 227–228
number of embryos transferred 171, 205
overwhelming emotions 204
patient–physician relationship 205–206
shared 176–177, 205–206
shared decision-making model 154–155
denominators 235
outcome measures 232, 234–235
depression 152, 161–163
dropout rate 166–167
pregnancy rate 163
developmental competence
development prolongation to blastocyst stage 26–29
embryo selection optimal scheme 41–42
fragmentation during cleavage 25–26
genomic mining for biomarkers 34–37
indicators at one-cell stage 22–23
intrafollicular milieu 29–31
metabolic approach to embryo selection 37
metabolic markers 32–34, 42
microscopically detectable determinants 20
mitochondria 37–40
molecular markers 32–34, 42
morphodynamic activities 23–25
morphological criteria in assessment 19–20, 42
non-invasive marker 17–19
perifollicular blood flow 30–31
predictive power of assessments 43
proteomic mining for biomarkers 34–37
selection in single embryo transfers 43
diabetes mellitus 7
digital power angiography, perifollicular microvasculature expansion 30–31
disability, chronic of child 204–205
disability-adjusted life year (DALY) 224
dispersmic penetration 20
distress 152
infertility 160–161
in vitro fertilization 161
DNA methylation 217
donor sperm 144
regulations 143
Doppler imaging, follicles 31
double blastocyst transfer (DBT)
comparison with single transfer 68
implantation rate 273
pregnancy rate 273
double (dual) embryo transfer (DET) 55, 61–62
birth weight comparison with SET 78–79
costs per patient 227
eDET comparison 63
health-economics 124, 159–160
human chorionic gonadotropin 84–85
implantation rate 85
incremental costs 227
obstetric outcomes 89
SET comparison 56, 68–71, 188
observational studies 71–72
single embryo transfer with consecutive transfer of
frozen-thawed 68
dropout rates, success impact 259
Dutch experience with SET 191–197
birth rate 192
clinical outcome 192–194
cost-effectiveness analysis 192, 192, 194, 196–197
mosting 194–195
cryopreservation 196
embryos
number transferred 191, 195, 195
quality 195–196
epidemiology 191–192
Maastricht experience in daily practice 195–196
mild stimulation protocol combination 193–194
natural cycle IVF 194
one cycle SET versus one cycle DET 193
pregnancy rate 195–197
randomized controlled trials 191–194
cost-effectiveness analysis 226–227
twin pregnancy rate 195
reduction 197
dystocia 6
 eclampsia, multiple pregnancies 6
economic evaluation types 224
educational group interventions 165
egg quality, age 95
elective double (dual) embryo transfer (eDET) 55, 61–62
elective single blastocyst transfer (eSBT) 61
pregnancy rate 273
elective single embryo transfer (eSET) xiii–xiv, 55–56
age factors 153, 274
attitude to 152–153
blastocyst culture contribution 98–100
characteristics 172–173
of couples 174–175
choice of 152–153
clinical guidelines 176
compelled 175–178
context 175–176
cryopreservation 122–123
non-optimal patients 123
programs 121
decision-making 171
definition 53, 55
DET comparison 63
disadvantage recognition by couples 173
dropout rates 159
embryo
biopsy impact 109–105
characteristics 273–274
quality 59
embryo selection 285–287
ethical barriers 175
evidence-based strategies 171–172
financial factors 153
financial stresses 160
health-economics 124, 159–160
human chorionic gonadotropin 84–85
implantation rate 85
implementation
barriers 171–179
difficulties 62–63
information provision to couples 175, 178
international differences 176
legislation 175–178
medical and compulsory SET distinctions 271
necessary extra cycles 175
oocytes
characteristics 273–274
donation 135
Index

elective single embryo transfer (eSET) (cont.)
  outcomes 99
    standardization of presentation 178–179
    US 271–272
  ovarian stimulation 94–98
  patients
    eligibility 160
    risk-taking attitude 153
    selection 67–68
  practice 284–285
  prediction models 178
  pregnancy rate 160, 172
  commercial interests 176
  preimplantation genetic screening (PGS) 100, 274
  professionals
    characteristics 173–174
    doubts 173–174
    information provision to couples 175
  prognostic models 173
  psychological context 151–152
  reasons for not implementing 160
  regulation 275–276
  reimbursement 178
    IVF/ICSI cycles 176–177
  religious barriers 175
  risk-taking attitude of patient 153
  selection criteria 173
    US 273–274
  success rate
    insufficient knowledge of couples 175
    professional lack of knowledge 174
    US 272
  outcomes 271–272
    selection criteria 273–274
    use increase 177–179
  visual aid 155
  elective single frozen embryo transfer (eSFET) 56, 140
  pregnancy rate 140
  embryo(s)
    assisted hatching 104
    availability of good quality 72
    available for cryopreservation 186
    bioactive molecule secretion 32
    blastulation 105
    cell size 115
    cleavage stage transfer compared with blastocysts 71
    cryostorage 95
    culture medium 217
  day 3 cleaving morphology 114–115
  demise 17–18
  epigenetic disturbances in cultured 217
  four-cell 113
  fragmentation during cleavage 25–26
  frozen-thawed 75, 95, 122, 287
  health-economics 124
  outcome 124
  US 272
  genome activation 244
  implantation
    potential 115
    rate of transferred 68
  mitochondrial content 39–40
  mitochondrial microzonation 40–41
  mitotic events 114–115
  monogenic disease mutation testing 101
  mosaic 103
  multiple replacement 17–18
  embryo biopsy
    after blastulation 101–103
    damage 101–103
    impact on eSET 100–105
    outcome 101
    timing 101–103
  embryo development
    laboratory 93–94
    prolongation to blastocyst stage 26–29
    sperm DNA anomalies 243–245
    with testicular sperm use 242–243
  embryo donation (ED) 56
    availability of embryos 139–140
    blastocyst transfer 140
    elective single frozen embryo transfer 140
  refreezing 140–141
  regulation/self-regulation 252
  SET impact 139–141
  embryo selection
    criteria 53, 273–274
    culture duration 214
    elective SET 285–287
    genetic methods 34–35
    implantation potential 55–57
    metabolic approach 37, 286
    molecular methods 34–35
    morphology role 42
    optimal scheme 41–42
    protocols 178
    SET concept 54–55
see also sequential embryo selection
embryo transfer
biopsied embryos 101
day 3
  comparison with blastocyst SET 214–215
pregnancy loss 215
scoring 115
take-home baby rate 96
delivery rate 123
epigenetic issues 216–217
imprinting issues 216–217
number transferred 63, 255
Belgian model 60
conditional treatment 206
decision-making 171, 205
decline in USA 271
doctor's decision 206
Dutch experience 191, 195, 195
eyear vanishing twin 84
first-trimester bleeding association 77, 77–78, 84
guidelines 257
Helsinki Hospital 122
IVF/ICSI 283–284
per cycle 139–140
pregnancy outcomes 77
  reduction 109–110, 276
  regulation/self-regulation 254–255
Swedish studies 163–184, 187
USA 271, 275–276
 optimum day 213–218
organelle content 39
outcome 122
oxygen consumption 39
prolonged culture 215
property rights 205
quality 59
after preimplantation genetic diagnosis 148
Dutch experience with SET 195–196
sperm origin 242–243
refreezing 140–141
research legislation 260
scoring on day 3 115
scoring systems 285–286
single with consecutive transfer of frozen-thawed SET 68
sperm anomalies influencing development 241–242
storage time limitation 258
substrate utilization 39
synchrony with uterus 214
vitrification 131
wastage 17–18
zona pellucida opening for biopsy 103–104
see also developmental competence
embryological outcomes 233
emotions/emotional states
  decision-making 153
  distress of in vitro fertilization 161
  overwhelming 204
endometrium, estrogen harmful effects 97–98, 105
depolarization reticulum
  abnormal aggregations of smooth surfaced 18
calcium release 41
epigenetic disturbances, cultured embryos 217
epigenetic issues, embryo transfer day 216–217
epigenetic reprogramming 217
equity 200–201
estradiol
  follicular response 95–97
  oocyte effects 95
estradiol receptors, endometrial 97–98
estrogen, endometrium effects 97–98, 105
European countries
cryopreservation 121
US comparison 274–276
evidence-based strategies for eSET 171–172
experimentation regulation on pre-embryo 253
family impact of multiple pregnancies 270
Federal Trade Commission (FTC) 256
Fertility Clinics Success Rate and Certification Act (1992, USA) 256
fertility of lesbians/single women 143–144
fetal growth
  curves 8
  restriction 8
fetal mortality, multiple pregnancies 7–8
fetal outcome, multiple pregnancies 7–10
fetal reduction
  multifetal pregnancy reduction 253, 276
  regulation/self-regulation 253
selective 19, 156
counseling 156
  regulation/self-regulation 253
fetoscopic selective laser photocoagulation of the vascular
  anastomoses at the intertwin membrane 10–11
fetus
  abnormalities in multiple pregnancies 9–10
  early loss 7
two viable in vanishing embryo syndrome 86
financial factors 259
elective single embryo transfer (eSET) 153
IVF/ICSI cycles 176–177
multiple births 270–271
public funding 201
stresses 160
Swedish experience of SET 187–189
triplets 270–271
twin pregnancies 270–271
see also cost(s); funding; health economics of SET; insurance coverage
first-trimester bleeding 77–78
adverse obstetric outcomes 84
incipient twin 84
number of embryos transferred 77, 77–78, 84
pregnancy outcomes 77
fluorescent in situ hybridization (FISH) 286
preimplantation genetic diagnosis 147
folate deficiency 6
follicles
Doppler imaging 31
oocyte segregation after retrieval 41–42
oxygen perfusion with angiogenesis stimulation 31
response to estradiol 95–97
follicle-specific cortisol:cortisone ratio 30
follicle-stimulating hormone (FSH), ovarian stimulation 94–95
follicular fluid
anti-Müllerian hormone 30
oxygenation 30–31
follicular granulosa cells, hypoxia-induced transcription factor (HIF) pathway 31
follicular phase stimulation 105
Food and Drug Administration (FDA) 256
frozen embryo transfers (FETs) 121
frozen-thawed 124
health-economics 124
outcome 123–124
full information criterion 202
funding
Belgian model 58, 58–59, 285
public 201
gamete intrafallopian transfer (GIFT), regulation/self-regulation 253
gametes
donation 252
sequential embryo selection 110–111
genetic counseling, multiple pregnancies 10
genetic screening, preimplantation 100
genetic testing, multiple pregnancies 10
genomic analysis
competence biomarkers 34–37
gene expression topology during oogenesis 36
Germany, legislation 260
gestational age
co-twin disappearance in vanishing twin syndrome 88
multiple pregnancies 8–9, 9, 9
goal replacement 204–205
gonadotropin-releasing hormone (GnRH) discontinuing at hCG trigger 95–97
ovarian stimulation 94–95
good clinical practice guidelines 201
granulosa cells, protein secretion 35
gremlin (GREM1) gene 34
grief response 151–152
guidelines
embryo numbers transferred 257
global regulation/self-regulation 250–251
multiple births 257
oversight 261
surveillance 255–256
US 256–257
health economics of SET 75, 159–160
analysis 223–225
decision-making 227–228
heavy load transfer (HLT) 62
HELLP syndrome, multiple pregnancies 6
hierarchy of interest 262, 261–263
higher-order gestations, perceptions 19
higher-order multiple births
incidence 3, 109
maternal complications 6–7
histone deacetylation 217
human chorionic gonadotropin (hCG) after eSET and DET 84–85
embryo secretion 32
multiple pregnancies 84
ovulating dose 95–97
singleton 84
Human Fertilisation and Embryology Act (UK) 258
human leukocyte antigen G (HLA-G), embryo competence marker 32–33
human life, value 275
hyaluronic acid synthetase (HAS2) gene 34
hydramnios, twin-to-twin transfusion syndrome 10–11
hypertensive disorders of pregnancy 6–7
hypoxia, intrafollicular 31
hypoxia-induced transcription factor (HIF) pathway 31
hysterectomy, emergent peripartum 6
implantation
blastocyst probability 99
early 83–89
first-trimester bleeding 78
implantation rate 97
age factor 96
blastocysts 131
cryopreservation 97, 124
DET 85
double blastocyst transfer 273
eSET 85
sperm origin 243
implantation window, early closure 98
imprinting
disorders 217
embryo transfer day 216–217
infertility treatment
information provision to couples 175, 178
cognitive dissonance affecting reception 202–203
cryopreservation 156
statistical 203
informed consent 153
barriers 202–203
insemination
lesbians 144
single women 144
insurance coverage 201, 251
US 251
international differences in eSET 176
intracytoplasmic sperm injection (ICSI) 75
age of female 174
characteristics of couples 174–175
context 175–176
reimbursement 176–177
testicular spermatozoa 242–243
vital fetuses 60
intraventricular hemorrhage, neonatal morbidity 9
iron deficiency 6
Italy, legislation 260
justice principle 201

stress 152, 162–163, 204
psychological 161–162
success 249–250
twins 12–13, 13
US 255
vital fetuses 60
incipient twin 83–85
first-trimester bleeding 84
obstetric outcomes 89
incremental cost-effectiveness ratio (ICER) 224–225, 227
infant mortality 7
multiple pregnancies 7–8
infertility
 coping strategies 165
distress 152, 160–161
personality profile 163
psychological impact 162
stress 163
infertility treatment
financial considerations 94
multiple births 3–4
see also assisted reproductive technology (ART); in vitro fertilization (IVF); intracytoplasmic sperm injection (ICSI)
information provision to couples 175, 178
cognitive dissonance affecting reception 202–203
cryopreservation 156
statistical 203
informed consent 153
barriers 202–203
insemination
lesbians 144
single women 144
insurance coverage 201, 251
US 251
international differences in eSET 176
intracytoplasmic sperm injection (ICSI) 75
age of female 174
characteristics of couples 174–175
context 175–176
reimbursement 176–177
testicular spermatozoa 242–243
vital fetuses 60
intraventricular hemorrhage, neonatal morbidity 9
iron deficiency 6
Italy, legislation 260
justice principle 201

stress 152, 162–163, 204
psychological 161–162
success 249–250
twins 12–13, 13
US 255
vital fetuses 60
incipient twin 83–85
first-trimester bleeding 84
obstetric outcomes 89
incremental cost-effectiveness ratio (ICER) 224–225, 227
infant mortality 7
multiple pregnancies 7–8
infertility
 coping strategies 165
distress 152, 160–161
personality profile 163
psychological impact 162
stress 163
infertility treatment
financial considerations 94
multiple births 3–4
see also assisted reproductive technology (ART); in vitro fertilization (IVF); intracytoplasmic sperm injection (ICSI)
information provision to couples 175, 178
cognitive dissonance affecting reception 202–203
cryopreservation 156
statistical 203
informed consent 153
barriers 202–203
insemination
lesbians 144
single women 144
insurance coverage 201, 251
US 251
international differences in eSET 176
intracytoplasmic sperm injection (ICSI) 75
age of female 174
characteristics of couples 174–175
context 175–176
reimbursement 176–177
testicular spermatozoa 242–243
vital fetuses 60
intraventricular hemorrhage, neonatal morbidity 9
iron deficiency 6
Italy, legislation 260
justice principle 201
index

legally enforced single embryo transfer (ISET) 57–61, 175–178
legislation 260
eSET 175–178
global regulation/self-regulation 250–251
research on embryos 260
social issues 258–259
lesbians 143–144
donor sperm 144
fertility status 143–144
insemination 144
in vitro fertilization 144
medical aspects 143–144
oocyte donation 144
live birth
cumulative per oocyte retrievals 235
outcome 233
primary criterion 237
rates 228
singleton 233–234
term 234
US rates 275
loss, feelings of 151–152
luteinizing hormone (LH), ovarian stimulation 94–95
malpresentation, multiple births 6
maternal complications 6–7
mortality with multiple births 235–236
multiple pregnancies 270
medical single embryo transfer (mSET) 57, 271
contraindications 57
metabolic markers, developmental competence 32–34, 42
mind–body interventions 164
stress reduction 167
miscarriage, risk with first-trimester bleeding 77
mitochondria
age effects 62
aggregation patterns 40–41
developmental competence 37–40
disproportionate segregation during cleavage 39–40
embryo content 39–40
local concentrations 40
local regulation of activity 40–41
microzonation in oocyte/early embryo 40–41
polarity 40–41
mitochondrial DNA (mtDNA) 38
copy numbers 39
oocyte content 38–39
molecular markers, developmental competence 32–34, 42
mood states 152
decision-making 153
morulae, scoring systems 116, 285–286
Müllerian inhibiting hormone 30
perifollicular flow rate 31
multifetal pregnancy reduction (MFPR) 276
regulation/self-regulation 253
multinucleation, aneuploidy 274
multiple births 13–14
complications 155
costs 225
counseling about risk 156
economic implications 270–271
frequency 19
guidelines 257
infertility treatment 3–4
maternal mortality 235–236
obstetric interventions 6
rates 185, 228
risk 4
solution to problem 276
success statistics 234
Swedish experience 183–184, 187, 227–228
trends 3–4
US 269, 272, 275–276
multiple embryo replacement 17–18
multiple pregnancies
birth weight 8–9
chorionicity 5, 8
cognitive development 12
complications 67
maternal 270
congenital malformations 270
costs 200, 225
counseling
about risk 156
in decision-making 153–155
genetic 10
Dutch experience 191
excess costs 159
family impact 270
fetal abnormalities 9–10
fetal outcome 7–10
 genetic counseling 10
genetic testing 10
gestational age 8–9, 9, 9
harm 200
human chorionic gonadotropin levels 84
hypertensive disorders 6–7
incidence 3, 109
IVF population at risk 67–68
long-term outcome 11–12
maternal risk 270
morbidity/mortality 5–7
mortality 7–8
neonatal outcome 7–10, 269–270
obstetric hemorrhage 6
outcomes 5, 13, 19
negative 284
neonatal 7–10, 269–270
preference 152–153, 207
information about risks 259
reduction 67, 75–76, 122–123
integrated approach 206
US 257
regulation 258
risks 3, 4, 152–153, 258
maternal 5–7, 270
minimization 200
perceived awareness 202
social development 12
US 269, 275
value of human life 275
zygosity 5

natural killer (NK) cells, sMIC activity 33
necrotizing enterocolitis 9
neonatal morbidity 9
neonatal mortality 7, 235–236
multiple pregnancies 7–8
neonatal outcome 79, 79
multiple pregnancies 7–10, 269–270
neonatal well-being 234
non-maleficence principle 200
nuchal translucency, twin-to-twin transfusion syndrome 10
nuclear (nucleolar) precursor bodies (NPs) 21
chromatin co-localization 24
chromosomal defect association 24
equatorial alignment 24–25
number 23–25
organization 23–25
peri-syngamic stage 24–25
pronuclear morphology 24–25
pronuclear stage embryo 23–25
score 23–24
scoring for sequential embryo selection 111–112
size 23–25
spatial abnormalities 24
nucleolar organizing regions (NORs) 112
nucleoli, functional components 112
numerators 233
outcome measures 232–234
obstetric hemorrhage, multiple pregnancies 6
obstetric interventions, multiple births 6
obstetric morbidity/mortality 5–7
obstetric outcomes 79, 79
one-cell stage, competence indicators 22–23
oocyte(s)
abnormal cytokinesis 113
ATP content 38–40
bioenergetic capacity 38–39
cryopreservation 35–36
cytoplasmic pH with intrafollicular hypoxia 31
dysmorphic 18
elective SET 273–274
estradiol effects 95
intrafollicular preparation 93–94
meiotic spindle 113
MII 18, 20–21
mitochondrial microzonation 40–41
mitotic spindle 112–113
morphological criteria for competence assessment 19–20
mtDNA content 38–39
polarized light microscopy 110–111
progesterone effects 95
retrieval 213
anxiety 163
total reproductive potential 250
scoring of fertilized 111, 111–112
segregation after retrieval 41–42
selection
criteria 273–274
genetic methods 34–35
by microarray and proteomic analysis 36–37
molecular methods 34–35
for sequential embryo selection 110–111
spindle visualization 110
see also zona pellucida
oocyte donation (OD) 135–137
  counseling 136
  embryo quality 136
  lesbian couples 144
  outcome 135–136
  pregnancy outcome 135
  recipients 135–137
    blastocyst transfer 136
    elective SET 135–136
    health conditions 135–136
    obstetric complications 136
    pregnancy rate 136
    twin rate 136
  regulation 252
  oogenesis, gene expression topology 36
  organelles
    embryo content 39
    ionic crosstalk 41
    severe clustering 18
  outcome
    alternative 236
    assisted reproductive technology 283–284
    complex 235
      eSET 99, 271–272
        standardization of presentation 178–179
      embryological 233
      health of children 284
      inconsistent reporting 237
      live birth 233
      measurement 250
      neonatal 79, 79
        multiple pregnancies 7–10, 269–270
      obstetric 79, 79
      oocyte donation 135–136
        per woman 235
      perception 235–236
      pregnancy 233
      process 237
      reporting 231–232
      singleton live birth 233–234
        term 234
      singletons 76–77, 78, 250
      obstetric 89
      success 250
      twin pregnancies 236
    outcome measures 233
      clarity/consistency 237
      cumulative outcome fresh + frozen 235
      data collection/analysis 236
      denominators 232, 234–235
        fresh cycle 235
        good 232
        criteria for 232
        numerators 232–234
        safety 235
        treatment effectiveness evaluation 237
      ovarian hyperstimulation 17, 213
        cytoplasmic dysmorphisms 18
        risk 71
      ovarian hyperstimulation syndrome 95–97
        follicular phase stimulation 105
        risk reduction 122
      ovarian stimulation 94–98
        benchmarks 94–95
        estradiol levels 98
        financial considerations 94
        long down regulation regimen 94–95
        markers of successful 233
        optimal 124
        ovulation enhancement, multiple births xiv
        ovulation induction, multiple births xiv
        ovulatory drugs xii, xii–xiv
    paternal influence 241
      animals 241–242
      humans 242–245
    patient(s)
      eligibility for eSET 160
      focus on pregnancy 205
      knowledge about risks/complications 202–203
      patient autonomy 154, 199–200
      rationality 201–205
      respect for 206–207
      risk acceptance decisions 201
      US 276
    patient education 201
      single blastocyst transfer 129–130
    patient selection for SET 67–73
      criteria 69
      good quality embryo availability 72
      observational studies 71–72
      older women 72
      potential candidates 67
      randomized clinical trials 68–71
      retrospective analysis 72
      sperm parameter consideration 245–246
    patient-friendly approach 199, 206
      patient–physician relationship 205–206
perifollicular blood flow
competent oocytes 31
developmental competence 30–31
embryo selection optimal scheme 41–42
follicle-specific differences 31
measurement 30–31
perifollicular microvasculature expansion 30–31
perinatal outcome after SET 75–80
placenta previa 6
placental abruption 6
placentation, first-trimester bleeding 78
platelet activating factor (PAF), embryo secretion 32
polarized light microscopy
microscopically detectable determinants of
competence 20
oocytes 110–111
zona pellucida 110–111
polycystic ovary syndrome 95–97
polymerase chain reaction (PCR) 286
preimplantation genetic diagnosis 147
population bias 76
practice standards, United States 256–257
pre-embryo, experimentation regulation 253
pregnancy
hypertensive disorders 6–7
IVF success marker 233
loss with embryo day 3 embryo transfer 215
outcome 77, 233
adverse 216–217
with oocyte donation treatment 135
singleton with incipient twin 85
patient focus 205
perinatal complications 216–217
psychological intervention effects 163–165
rate with cryopreservation 122–123
two gestational sacs 86–87
pregnancy rate
anxiety 163
decrease 172
depression 163
double blastocyst transfer 273
Dutch experience with SET 195–197
elective single blastocyst transfer 273
eSET 160, 172
commercial interests 176
mind–body interventions 164
per cycle 75, 178
psychosocial interventions 164–165
SET 71
sperm origin 243
preimplantation genetic aneuploidy screening (PGS) 147, 149, 286
indications 148
preimplantation genetic diagnosis (PGD) 147–149, 286–287
clinical application 147
indications 148
outcome 148–149
procedure 147–148
regulation/self-regulation 253
preimplantation genetic screening 100, 286
chromosomal abnormalities 147
eSET 274
preterm birth
delivery 8
prevention 6
singletons 234
in vanishing twin syndrome 87, 88
twin pregnancies 234, 270
preterm labor, spontaneous 8
preterm premature rupture of the membranes (PPROM) 8
process outcome 237
progesterone
endometrial effect early termination 98
oocyte effects 95
progesterone receptors, endometrial 97–98
pronuclei
alignment at syngamy 23
intracytoplasmic motion 23
morphology 24–25
orientation 22
scoring for sequential embryo selection 111–112
prospect theory, risk behavior 204–205
proteomic analysis, competence biomarkers 34–37
psychological crisis 151–152
psychological defense mechanisms 152
psychological interventions, effects on
pregnancy 163–165
psychological stress, in vitro fertilization 161–162
psychosocial interventions
educational group 165
effectiveness 165–166
effects on pregnancy 163–165
groups benefiting 166
pregnancy rate 164–165
psychosocial risk, counseling 156
public funding 201
quality of care, process indicators 232
quality of life, Swedish experience 187
quality-adjusted life year (QALY) 224
randomized controlled trials (RCT)
comparison of SET and DET 68–71
cost-effectiveness analysis 225–226
Dutch studies 191–194
mild stimulation protocol combination 193–194
multiple birth rates 226
natural cycle IVF 194
one cycle SET versus one cycle DET 193
Scandinavian SET study 184–185
SET versus DET 226
rationality 201–205
desire for twins 201–202
goal replacement 204–205
knowledge
of real-life implications 203
of risks/complications 202–203
overwhelming emotions 204
reactive oxygen species (ROS) 98–99
ATP focal regulation 41
reduction, spontaneous 83
registration of practice 284
regulation
advantages 257–258
of ART 249
blastocyst transfer 252
conceptus status 253–254
cryopreservation 251–252
data collection methods 250
definition 249
disadvantages 258–259
eSET 275–277
embryos
donation 252
numbers transferred 254–255
gamete intrafallopian transfer 253
global 250
multifetal pregnancy reduction 253
multiple pregnancies 258
preimplantation genetic diagnosis 253
reproductive tourism 254, 258–259
self-regulation comparisons 259
social issues 258–259
US 256–257, 275–276
welfare of child 252
regulations, international 255–256
reimbursement
eSET 178
IVF/ICSI cycles 176–177
relaxation training 163–164
reproductive tourism 143–144, 176
regulation 254, 258–259
self-regulation 254
respiratory distress syndrome, neonatal morbidity 9
retinoblastoma 217
rhesus iso-immunization, vanishing twin syndrome 86
risk behavior 204–205
risks
minimization in multiple pregnancies 200
patient knowledge 202–203
value placed on 205
safety, measure 235
Scandinavian SET study 184–185
quality of life 187
selective fetal reduction 19
conceptus status 253–254
cryopreservation 251–252
data collection methods 250
preimplantation genetic diagnosis 253
reproductive tourism 254
SET implementation 249
stakeholders 261–263
US 261, 263
welfare of child 252
sepsis, neonatal morbidity 9
sequential embryo selection 109–116
blastocyst
  morphology 115–116
  selection 115–116
  cleavage
    early 112
    first and second mitotic 112–114
day 3 cleaving embryo morphology 114–115
fertilized oocyte scoring 111–112
gamete selection 110–111
oocyte selection 110–111
sperm selection 110
shared decision-making (SDM) 154–155
single blastocyst transfer (SBT) 61
  blastocyst evaluation 132
  comparison with double transfer 68
  comprehensive incentive program 129–130
cryo-augmentation impact 131–132
  live birth rate 131
  outcomes 130, 132
  twin rate 131–132
  US experience 127–130
single embryo transfer (SET)
  concept 54–55
  definition 53–54
  target population 54
  indications 71–72
  target population 54
single women 143–144
donor sperm 144
  fertility status 143–144
  insemination 144
  in vitro fertilization 144
  medical aspects 143–144
singleton live birth 233–234
term 234
singleton
  birth weight 78–79, 234
  from single gestation/loss of one gestational sac 87
  cerebral palsy in vanishing twin syndrome 88–89
  congenital malformations 89
  human chorionic gonadotropin levels 84
  incipient twin 85
  IVF beginning as higher-order gestation 86–87
  neonatal mortality 235–236
  outcomes 76–77, 78, 250
  obstetric 89
  population bias 76
  preterm birth 87, 88, 234
vanishing twin syndrome 76–77, 87, 88
  small-for-gestational-age babies, vanishing twin
    syndrome 88
  social development, multiple pregnancies 12
  social issues, regulation 258–259
  Society for Reproductive Technology (SART) 256–257
  programs 256–257
  solidarity principle 200
  Spain, legislation 260
sperm
  animals 241–242
  anomalies influencing embryo development 241–242
  DNA anomalies 244
    embryo development 243–245
    DNA integrity tests 245
    DNA strand breaks 243–245
    donor 143–144
    embryo quality 242–243
    nuclear integrity 243
    parameter consideration in patient selection 245–246
    quality and blastocyst development 244–245
    rapid linear motion 20
    SCSA 244–245
    testicular 242–243
    TUNEL assay 244–245
  sperm chromatin structure assay (SCSA) 244–245
  sperm parameters 241–246
  sperm selection, sequential embryo selection 110
  spindle
    birefringence imaging 31
    MII 20–21
  stakeholders, self-regulation 261–263
  statistical information 203
  stillbirths 7
  multiple pregnancies 7–8
stress
  biological end point influence 162
  financial 160
  infertility 163
  management 165
  psychological with in vitro fertilization 161–162
  questionnaire 188
  reduction 165–168
  mind–body interventions 167
  techniques 159–165, 168
  in vitro fertilization 152, 162–163, 204
  stress-inducible soluble major histocompatibility complex
    Class I chain-related molecule (sMIC) 33–34, 42
subfertility, obstetric outcomes 89
Index

success 232, 231–238, 249–250, 250

dropout rates 259

multiple births 234

outcomes 250

reporting 232, 231–232

inconsistent 237

in vitro fertilization 249–250

Swedish experience of SET 183–189

attitudes 187

birth rate 186

costs 187–189

embryo transfer numbers 187

insurance coverage 251

multiple births 187

reduction 227–228

observational studies 185

quality of life 187

randomized controlled trials, cost-effectiveness analysis 226–227

Scandinavian SET study 184–185

stress questionnaire 188

treatment effectiveness evaluation 237

triple embryo transfer (TET) 62

triplets xii

decline in US 271

family impact 270

financial factors 270–271

incidence 3

in Belgium 59

maternal complications 6–7

TUNEL assay 244–245

Turner syndrome 136

oocyte recipients 136

twin pregnancies

ART 12–13

versus spontaneous 12–13

blastocyst transfer 129

cerebral palsy risk 11–12

complications 171

incidence 172–173

patient estimates 202

view of couples 174–175

consideration as successful outcome 174–175, 236

costs 225

for society 75

Dutch experience with SET 195

eyearly unrecognized 83–85

excess costs 159

financial factors 270–271

first/second cycles 68

impact on embryo donation 140

incidence 109

knowledge of real-life implications 203

morbidity 270

oocyte recipients 136

outcomes 13, 76

patient preference 200

population bias 76

preterm births 234, 270

prevention 160

rate in USA 271

reduction 75–76, 171, 285

Dutch experience 197

US 257

risks 128–129

insufficient knowledge of couples 175

professional lack of knowledge 174

single blastocyst transfer 131–132

transfer of two blastocysts 128–129

US programs 127, 272

twin-prone patient 54, 75

twins xii

dizygotic 4–5

congenital malformations 9–10

European births 4

family impact 270

growth restriction 8

incidence 3

in Belgium 59

intrapair birth weight discordance 8–9

monoamniotic 11

monozygotic 4–5

blastocyst transfer 215–216

congenital malformations 9–10

placental development 216

vanishing twin syndrome 87

mortality 8

neonatal 235–236

raising 203

rationality of desire for 201–202

see also incipient twin; vanishing twin syndrome

twin-to-twin transfusion syndrome (TTTS) 10–11

ultrasound

twin-to-twin transfusion syndrome 10

vanishing twin syndrome 86
United States
  cost-effectiveness analysis 228
eSET 272
  outcomes 271–272
  selection criteria 273–274
elective single blastocyst transfer 127–128, 272–273
embryo numbers transferred 271, 275
embryos, use of frozen-thawed 272
European comparisons 274–276
experience of SET 269–277
guidelines 256–257
insurance coverage 251
live birth rates 275
multiple births 272, 276
multiple pregnancies 269, 275
patient selection 274
practice standards 256–257
reasons for SET 269–271
regulation 256–257, 275–276
self-regulation 261, 263
twin pregnancies 127, 272
in vitro fertilization 253
world comparisons 274–276
uterus
  atony 6
  embryo transfer synchrony 214
  utility principle 200
vanishing embryo syndrome 85
vanishing twin syndrome 7, 76–77, 83, 85–89
cerebral palsy 88–89
chromosomal abnormalities 86
diagnosis 86–87
frequency 86–87
gestational age 88
gestational sac number 87
neurological sequelae 88–89
obstetric complications 87–89
outcomes 87–89
pathology 85–86
preterm birth 88
rhesus iso-immunization 86
small-for-gestational-age babies 88
two gestational sacs 86–87
two viable fetuses 86
vitrification, blastocysts and embryos 131, 287
women, single 143–144
donor sperm 144
fertility status 143–144
insemination 144
in vitro fertilization 144
medical aspects 143–144
zygosity 4–5
congenital malformations 9–10